Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5699077 | Clinical Oncology | 2012 | 5 Pages |
Abstract
Recombinant human thyroid-stimulating hormone-stimulated 18F-FDG PET/CT detected recurrent disease in most patients. Although subsequent treatment of 18F-FDG PET/CT-detected disease reduced tumour marker levels in most patients, markers remained detectable, suggesting that not all residual or metastatic disease had been identified, which compromised salvage therapy. This is the largest and most mature study to date reporting tumour marker responses to PET- or PET/CT-guided therapy in this setting.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
K. Dennis, J.H. Hay, D.C. Wilson,